Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05117476 · ClinicalTrials.gov registry record · Phase 1
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor and NSCLC, sponsored by Cullinan Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 440
- Enrollment target
- 20
- Study locations
NCT05117476: Active Phase 1 study of Advanced Solid Tumor and NSCLC, sponsored by Cullinan Therapeutics.
NCT05117476 is a Phase 1 study of Advanced Solid Tumor and NSCLC that is active but no longer recruiting, run by Cullinan Therapeutics. The registered enrollment target is 440 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (130% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05117476, a Phase 1 study of Advanced Solid Tumor and NSCLC, is active but no longer recruiting, sponsored by Cullinan Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 440 participants
- Enrollment target
- 20
- Study locations
Study Summary
CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.
Primary Outcome
Number of treatment-emergent events (TEAEs) TEAE is defined as adverse events reported for the first time or worsening of a pre-existing event after the first dose of study drug.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Paclitaxel
- DRUG pemetrexed
- DRUG CLN-619
- DRUG Carboplatin AUC 6
Study Locations (20)
Other
- Biokinetica - Józefów
- Med-Polonia Sp. zo. o. - Poznan
- Narodowy Insytut Onkologii im Marii Sklodowskiej-Curie - Warsaw
- START Barcelona - Barcelona
California
- City of Hope - Duarte
- City of Hope - Irvine
Victoria
- Monash Health - Clayton
- Alfred Health - Melbourne
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- Florida Cancer Specialists - Sarasota
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- START Midwest - Grand Rapids
New Jersey
- Hackensack Meridian Health - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2021-10-29 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What the registry record for NCT05117476 still lists
NCT05117476 is an interventional study that assigns participants to a tested intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (130% higher).
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT05117476 names 20 study sites across 15 states, led by Other, California, Victoria.
Frequently Asked Questions
What is clinical trial NCT05117476 about?
NCT05117476 is a clinical study titled "A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors". CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.
What is the current status of trial NCT05117476?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 440 participants. The study started on 2021-10-29. Estimated completion is 2026-06.
What conditions does trial NCT05117476 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, NSCLC.
What interventions are being tested in trial NCT05117476?
The interventions under investigation include: Pembrolizumab (DRUG), Paclitaxel (DRUG), pemetrexed (DRUG), CLN-619 (DRUG), Carboplatin AUC 6 (DRUG).
Who is sponsoring clinical trial NCT05117476?
This trial is sponsored by Cullinan Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05117476 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05117476's enrollment target sits among peer trials
440 14th of 189 higher than 176 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
- NCT05624879 · 440 participants · NA
Accelerated Resolution Therapy for Early Maladaptive Grief
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI